Allergan plc. (NYSE:AGN)

Real-time price: | Most recent change:0.00%

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, central nervous system, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; In addition, it develops medical and cosmetic treatments; treatments for neurodegenerative disorders; and inflammatory and fibrotic diseases. It has a collaboration, option, and license agreement with Lyndra, Inc. to develop orally administered products for the treatment of Alzheimer's disease; strategic alliance and option agreement with Editas Medicine, Inc.; and Allergan plc also has licensing agreements with Assembly Biosciences, Inc. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was incorporated in 2013 and is headquartered in Dublin, Ireland....

+See More


Here we provide our AYA proprietary alpha stock signals for all premium members on our AYA fintech network platform. Specifically, a high Fama-French multi-factor dynamic conditional alpha suggests that the stock is likely to consistently outperform the broader stock market benchmarks such as S&P 500, Dow Jones, Nasdaq, Russell 3000, MSCI USA, and MSCI World etc. Since March 2023, our proprietary alpha stock signals retain U.S. Patent and Trademark Office (USPTO) fintech patent protection, approval, and accreditation for 20 years. Our homepage and blog articles provide more details on this proprietary alpha stock market investment model with robust long-term historical backtest evidence.

Sharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 8 August 2026

Blog+More

Former Bank of England Governor Mervyn King provides his deep substantive analysis of the Global Financial Crisis of 2008-2009.

Monica McNeil

2023-03-07 11:29:00 Tuesday ET

Former Bank of England Governor Mervyn King provides his deep substantive analysis of the Global Financial Crisis of 2008-2009.

Former Bank of England Governor Mervyn King provides his deep substantive analysis of the Global Financial Crisis of 2008-2009. Mervyn King (2017) &nb

+See More

Modern themes and insights in behavioral finance (Part 1)

Laura Hermes

2022-02-05 09:26:00 Saturday ET

Modern themes and insights in behavioral finance (Part 1)

Modern themes and insights in behavioral finance   Shiller, R.J. (2003). From efficient markets theory to behavioral finance. Journal of Economi

+See More

Federal Reserve remains patient on future interest rate adjustments due to trade and fiscal budget negotiations.

Becky Berkman

2019-02-04 07:42:00 Monday ET

Federal Reserve remains patient on future interest rate adjustments due to trade and fiscal budget negotiations.

Federal Reserve remains patient on future interest rate adjustments due to global headwinds and impasses over American trade and fiscal budget negotiations.

+See More

AYA fintech finbuzz analytic report on the global macro economic outlook Summer-Fall 2019

Andy Yeh Alpha

2019-08-07 08:32:00 Wednesday ET

AYA fintech finbuzz analytic report on the global macro economic outlook Summer-Fall 2019

Our fintech finbuzz analytic report shines fresh light on the current global economic outlook. As of Summer-Fall 2019, the current analytic report focuses o

+See More

Today, tech titans continue to reshape and even disrupt global pharmaceutical investments for both better healthspan and longer lifespan.

John Fourier

2026-10-31 12:38:00 Saturday ET

Today, tech titans continue to reshape and even disrupt global pharmaceutical investments for both better healthspan and longer lifespan.

Today tech titans and billionaires continue to reshape global pharmaceutical investments for both better healthspan and longer lifespan. We discuss, desc

+See More

Business entrepreneurs dare to dream, remain true and authentic to themselves, and try to make a great social impact in the world.

Charlene Vos

2020-07-05 11:31:00 Sunday ET

Business entrepreneurs dare to dream, remain true and authentic to themselves, and try to make a great social impact in the world.

Business entrepreneurs dare to dream, remain true and authentic to themselves, and try to make a great social impact in the world. Alex Malley (2014)

+See More